Ocrevus, Kesimpta, and Briumvi all deplete B-cells to manage MS, but they’re not interchangeable. Ocrevus covers both relapsing and primary progressive MS, while Kesimpta and Briumvi target relapsing forms only. Each differs in how it’s delivered — infusion versus self-injection — and in cost, ranging from roughly $71,000 to $88,000 annually. Efficacy data shows all three markedly reduce relapses and lesions. The right choice depends on your specific MS type, lifestyle, and financial situation — and the details matter more than you’d expect.
Which MS Types Do Ocrevus, Kesimpta, and Briumvi Treat?
When comparing Ocrevus, Kesimpta, and Briumvi, their approved indications differ in meaningful ways.
As disease-modifying therapies targeting B-cell activity, each addresses distinct multiple sclerosis subtypes.
Ocrevus stands apart as the only B-cell therapy among the three approved for both relapsing forms and primary progressive MS, making it the broadest treatment option available.
Ocrevus is the only B-cell therapy approved for both relapsing forms and primary progressive MS.
Kesimpta is indicated exclusively for relapsing forms of multiple sclerosis, including clinically isolated syndrome, but doesn’t extend to progressive disease.
Briumvi targets clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS, offering a focused approach for specific subtypes.
Understanding these distinctions matters when you’re guiding patients toward appropriate treatment options.
Matching the right B-cell therapy to each patient’s specific MS subtype directly impacts their long-term outcomes.
How Is Each Drug Given: and How Often?
How each B-cell therapy is administered differs notably, and those differences carry real implications for patient adherence. Understanding administration methods helps you guide patients toward realistic treatment schedules.
Ocrevus requires intravenous infusion every six months, but the initial dose splits into two infusions two weeks apart, each lasting roughly two hours.
Briumvi follows a similar intravenous infusion schedule—one hour per session every six months—with an initial infusion followed by a larger one two weeks later.
Kesimpta takes a different approach entirely. This subcutaneous injection is self-administered at home, beginning with weekly doses for three weeks, then shifting to monthly injections.
That flexibility notably improves patient convenience compared to clinic-based B-cell therapy options. When frequency of doses and lifestyle demands matter, Kesimpta’s model deserves serious consideration.
How Well Do Ocrevus, Kesimpta, and Briumvi Actually Work?
Efficacy ultimately determines whether a therapy earns its place in your treatment toolkit. All three treatments deliver compelling results against multiple sclerosis relapses.
Ocrevus reduced relapses by 46% versus Rebif, cut disability progression by 40%, and achieved an annualized relapse rate of just 0.09 after two infusions.
Ocrevus cut relapses by 46%, slashed disability progression by 40%, and drove annualized relapse rates down to just 0.09.
Kesimpta reduced relapses by 51%-58% compared to teriflunomide, demonstrating strong disease activity control.
Briumvi matched that performance, reducing relapses by 49%-59%, with over 60% of patients showing no evidence of disease activity at 96 weeks.
Each therapy also notably reduced T1 Gd+ lesions.
When weighing safety profiles and treatment costs alongside these numbers, the efficacy data positions all three as genuinely powerful options for your patients.
What Side Effects Do Ocrevus, Kesimpta, and Briumvi Cause?
Understanding the side effect profiles of these three therapies helps you counsel patients before initiating treatment. Ocrevus and Briumvi both cause infusion reactions, fever, chills, and respiratory infections, given their intravenous administration.
Kesimpta, administered subcutaneously, typically produces milder injection site reactions like swelling and itching, along with headaches.
A major difference worth noting: Ocrevus carries rare but documented cases of progressive multifocal leukoencephalopathy (PML), while Kesimpta has no reported PML cases.
Briumvi’s PML risk profile remains under continued surveillance.
All three therapies share a risk of infections stemming from B-cell depletion, increasing patients’ susceptibility to colds and bronchitis.
I’d also emphasize monitoring for hepatitis B reactivation and tuberculosis across all three, as these serious adverse effects demand proactive clinical attention.
Which Drug Makes Most Sense for Your MS Type and Budget?
When selecting among Ocrevus, Kesimpta, and Briumvi, MS type and cost are two decisive factors I’d weigh first.
If your patient has primary progressive MS, Ocrevus is the only viable option among these three, as Briumvi and Kesimpta are approved solely for relapsing MS.
For relapsing MS, all three become contenders, and efficacy data strengthen each case—Briumvi demonstrated a 59% relapse reduction versus teriflunomide, while Kesimpta achieved an annualized relapse rate of just 0.09.
Cost also shapes treatment choices considerably. Briumvi’s annual list price reaches approximately $88,000, compared to Ocrevus’s $71,187.
Kesimpta’s flexible self-administration may offset infusion schedule burdens.
Weighing your patient’s MS subtype, financial constraints, and administration preferences together produces the most clinically sound, patient-centered recommendation.
Frequently Asked Questions
Is Briumvi More Effective Than Ocrevus?
Like two sharp scalpels cutting through disease activity, both therapies perform impressively—but the data doesn’t clearly crown Briumvi superior.
Briumvi achieved an 80% reduction in annualized relapse rates and demonstrated non-inferiority to Ocrevus, which reduces relapses by approximately 70%.
Over 60% of Briumvi patients showed no evidence of disease activity at 96 weeks.
I’d say they’re comparably effective, with patient-specific factors ultimately guiding your therapeutic decision.
What Is the Safest Multiple Sclerosis Medication?
Based on the evidence, I’d point you toward Kesimpta as the safest option among these three B-cell therapies.
It has no reported PML cases, unlike Ocrevus, which carries that serious brain infection risk. Its subcutaneous self-administration also eliminates infusion-related complications seen with Ocrevus.
Briumvi requires careful monitoring due to fever, chills, and respiratory infections.
However, I’d strongly encourage you to consult your neurologist, as individual patient factors always guide the safest choice.
Is Briumvi Better Than Kesimpta?
Neither’s definitively “better” — it’s like choosing between a scalpel and a laser; both cut precisely, but the tool depends on the surgeon’s need.
Briumvi reduces relapses by 49%-59% with twice-yearly infusions and earns perfect 10/10 satisfaction scores, but costs ~$88,000 annually.
Kesimpta achieves 51%-58% reduction, costs ~$71,187, offers monthly self-injection flexibility, and carries no PML risk reported.
I’d recommend matching the therapy to your patient’s lifestyle, safety profile, and financial realities.
How Much Does Briumvi Cost Without Insurance?
Without insurance, Briumvi’s list price runs approximately $88,000 per year, making it financially prohibitive for most patients.
If you’re uninsured, you’ll likely face costs exceeding $80,000 annually.
However, I’d encourage you not to let that number discourage you.
Viatris offers co-pay assistance programs that can cover up to $18,000 annually for eligible patients, potentially reducing your burden considerably.
I’d recommend contacting Viatris directly to explore your assistance options.
